目的 探讨卡瑞利珠单抗联合XELOX方案治疗晚期结肠癌的临床疗效。方法 选取2021年1月-2023年1月京山市人民医院收治的94例结肠癌患者,随机分为对照组(47例)和治疗组(47例)。对照组患者采用XELOX方案治疗,第1天静脉滴注注射用奥沙利铂,130 mg/m²;第1~14天早、晚餐后口服卡培他滨片,1 000 mg/m²,2次/d。治疗组在对照组基础上静脉滴注注射用卡瑞利珠单抗,200 mg/次,1次/3周,滴注2次。两组患者均治疗6周。观察两组患者临床疗效,比较治疗前后两组患者血清大肠特异性抗原-2(CCSA-2)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、血管内皮生长因子(VEGF-A)、VEGF受体2(VEGFR2)及生活质量核心量表(QLQ-C30)评分。结果 治疗后,治疗组疾病控制率为80.85%,较对照组的61.70%明显升高(P<0.05)。治疗后,两组患者血清CCSA-2、CEA、CA19-9、VEGF-A、VEGFR2水平均较治疗前明显降低(P<0.05),且治疗组较对照组下降更显著(P<0.05)。治疗后,两组患者QLQ-C30评分均较治疗前明显升高(P<0.05),且治疗组较对照组升高更显著(P<0.05)。结论 卡瑞利珠单抗联合XELOX方案可有效改善晚期结肠癌患者血清中异常肿瘤标志物及VEGF-A、VEGFR2等血管生长因子水平,提高生活质量,疗效显著。

Objective To explore the clinical efficacy of camrelizumab combined with XELOX regimen in treatment of advanced colon cancer. Methods Patients (94 cases) with advanced colon cancer in People's Hospital of Jingshan from January 2021 to January 2023 were randomly divided into control (47 cases) and treatment (47 cases) group. Patients in the control group were administered with XELOX regimen, Oxaliplatin for injection was given intravenously on 1 d, 130 mg/m²; Capecitabine Tablets were taken orally after breakfast and dinner on 1-14 d, 1 000 mg/m², twice daily. Patients in the treatment group were iv administered with Camrelizumab for injection on the basis of the control group, 200 mg/time, once every 3 weeks. Patients in two groups were treated for 6 weeks. After treatment, the clinical evaluations were evaluated, the levels of serum CCSA-2, CEA, CA19-9, VEGF-A and VEGFR2, and the QLQ-C30 scores in two groups before and after treatment were compared. Results After treatment, the disease control rate of the treatment group was 80.85%, which was significantly higher than that of the control group (61.70%, P < 0.05). After treatment, the serum levels of CCSA-2, CEA, CA19-9, VEGF-An and VEGFR2 in two groups were significantly lower than those before treatment (P < 0.05), and the decrease in the treatment group was more significant than that in the control group (P < 0.05). After treatment, QLQ-C30 scores in two groups were significantly higher than those before treatment (P < 0.05), and the level in the treatment group was significantly higher than that in the control group (P < 0.05). Conclusion Camrelizumab combined with XELOX regimen can effectively improve the serum levels of abnormal tumor markers and vascular growth factors such as VEGF-An and VEGFR2 in patients with advanced colon cancer, and improve the quality of life.

R979.1

湖北省卫生健康委科研项目（WJ2021F119）